25 XP   0   0   10

Galapagos N.V.
Buy, Hold or Sell?

Let's analyse Galapagos N.V. together

PenkeI guess you are interested in Galapagos N.V.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Galapagos N.V.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Galapagos N.V.

I send you an email if I find something interesting about Galapagos N.V..

Quick analysis of Galapagos N.V. (30 sec.)










What can you expect buying and holding a share of Galapagos N.V.? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€39.78
Expected worth in 1 year
€38.74
How sure are you?
46.2%

+ What do you gain per year?

Total Gains per Share
€-1.04
Return On Investment
-2.9%

For what price can you sell your share?

Current Price per Share
€36.40
Expected price per share
€30.11 - €36.70
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Galapagos N.V. (5 min.)




Live pricePrice per Share (EOD)

€36.40

Intrinsic Value Per Share

€-2.57 - €0.32

Total Value Per Share

€37.22 - €40.10

2. Growth of Galapagos N.V. (5 min.)




Is Galapagos N.V. growing?

Current yearPrevious yearGrowGrow %
How rich?$2.8b$2.8b-$89.1m-3.2%

How much money is Galapagos N.V. making?

Current yearPrevious yearGrowGrow %
Making money-$41.2m$1.4m-$42.7m-103.6%
Net Profit Margin-45.0%0.5%--

How much money comes from the company's main activities?

3. Financial Health of Galapagos N.V. (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#24 / 1068

Most Revenue
#67 / 1068

Most Profit
#931 / 1068

Most Efficient
#574 / 1068
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Galapagos N.V.? (5 min.)

Welcome investor! Galapagos N.V.'s management wants to use your money to grow the business. In return you get a share of Galapagos N.V..

What can you expect buying and holding a share of Galapagos N.V.?

First you should know what it really means to hold a share of Galapagos N.V.. And how you can make/lose money.

Speculation

The Price per Share of Galapagos N.V. is €36.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Galapagos N.V..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Galapagos N.V., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €39.78. Based on the TTM, the Book Value Change Per Share is €-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is €0.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Galapagos N.V..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.421.2%-0.63-1.7%0.020.1%-0.28-0.8%-0.18-0.5%
Usd Book Value Change Per Share0.611.7%-0.28-0.8%0.300.8%1.173.2%1.032.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.611.7%-0.28-0.8%0.300.8%1.173.2%1.032.8%
Usd Price Per Share35.03-39.46-54.50-91.56-74.50-
Price to Earnings Ratio20.75-40.81--8.11-12.38-2.23-
Price-to-Total Gains Ratio56.99-57.02-3,163.10-596.36-359.82-
Price to Book Ratio0.82-0.94-1.26-2.55-4.06-
Price-to-Total Gains Ratio56.99-57.02-3,163.10-596.36-359.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share39.19188
Number of shares25
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.281.17
Usd Total Gains Per Share-0.281.17
Gains per Quarter (25 shares)-7.0229.27
Gains per Year (25 shares)-28.10117.10
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-28-380117107
20-56-660234224
30-84-940351341
40-112-1220468458
50-140-1500585575
60-169-1780703692
70-197-2060820809
80-225-2340937926
90-253-262010541043
100-281-290011711160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%7.05.00.058.3%9.011.00.045.0%12.017.010.030.8%18.018.038.024.3%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%11.09.00.055.0%18.018.03.046.2%27.028.019.036.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.074.00.0%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%11.09.00.055.0%18.018.03.046.2%27.028.019.036.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Galapagos N.V.

About Galapagos N.V.

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of"various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Fundamental data was last updated by Penke on 2023-11-30 21:37:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Galapagos N.V..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Galapagos N.V. earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Galapagos N.V. to the Biotechnology industry mean.
  • A Net Profit Margin of 21.5% means that €0.22 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Galapagos N.V.:

  • The MRQ is 21.5%. The company is making a huge profit. +2
  • The TTM is -45.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ21.5%TTM-45.0%+66.5%
TTM-45.0%YOY0.5%-45.5%
TTM-45.0%5Y-39.6%-5.4%
5Y-39.6%10Y-23.5%-16.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.5%-162.5%+184.0%
TTM-45.0%-213.8%+168.8%
YOY0.5%-276.3%+276.8%
5Y-39.6%-472.2%+432.6%
10Y-23.5%-616.6%+593.1%
1.1.2. Return on Assets

Shows how efficient Galapagos N.V. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Galapagos N.V. to the Biotechnology industry mean.
  • 0.6% Return on Assets means that Galapagos N.V. generated €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Galapagos N.V.:

  • The MRQ is 0.6%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.6%TTM-0.8%+1.4%
TTM-0.8%YOY0.0%-0.8%
TTM-0.8%5Y-0.6%-0.2%
5Y-0.6%10Y-0.4%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6%-12.5%+13.1%
TTM-0.8%-12.0%+11.2%
YOY0.0%-11.1%+11.1%
5Y-0.6%-13.6%+13.0%
10Y-0.4%-15.0%+14.6%
1.1.3. Return on Equity

Shows how efficient Galapagos N.V. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Galapagos N.V. to the Biotechnology industry mean.
  • 1.0% Return on Equity means Galapagos N.V. generated €0.01 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Galapagos N.V.:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.0%TTM-1.5%+2.5%
TTM-1.5%YOY0.0%-1.6%
TTM-1.5%5Y-0.9%-0.6%
5Y-0.9%10Y-0.6%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-15.6%+16.6%
TTM-1.5%-15.0%+13.5%
YOY0.0%-14.0%+14.0%
5Y-0.9%-18.5%+17.6%
10Y-0.6%-19.5%+18.9%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Galapagos N.V..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Galapagos N.V. is operating .

  • Measures how much profit Galapagos N.V. makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Galapagos N.V. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Galapagos N.V.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-21.7%+21.7%
TTM-5Y-35.8%+35.8%
5Y-35.8%10Y-26.4%-9.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--291.2%+291.2%
TTM--288.2%+288.2%
YOY-21.7%-283.2%+261.5%
5Y-35.8%-456.3%+420.5%
10Y-26.4%-556.2%+529.8%
1.2.2. Operating Ratio

Measures how efficient Galapagos N.V. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.30 means that the operating costs are €1.30 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Galapagos N.V.:

  • The MRQ is 1.299. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.433. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.299TTM1.433-0.134
TTM1.433YOY1.247+0.186
TTM1.4335Y1.740-0.307
5Y1.74010Y1.730+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2992.833-1.534
TTM1.4333.255-1.822
YOY1.2473.774-2.527
5Y1.7405.926-4.186
10Y1.7307.671-5.941
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Galapagos N.V..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Galapagos N.V. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.91 means the company has €8.91 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Galapagos N.V.:

  • The MRQ is 8.909. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.363. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.909TTM8.363+0.546
TTM8.363YOY8.410-0.047
TTM8.3635Y8.367-0.004
5Y8.36710Y5.754+2.613
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.9093.998+4.911
TTM8.3634.454+3.909
YOY8.4105.624+2.786
5Y8.3676.239+2.128
10Y5.7546.589-0.835
1.3.2. Quick Ratio

Measures if Galapagos N.V. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Galapagos N.V. to the Biotechnology industry mean.
  • A Quick Ratio of 8.33 means the company can pay off €8.33 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Galapagos N.V.:

  • The MRQ is 8.331. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.689. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.331TTM7.689+0.642
TTM7.689YOY6.042+1.647
TTM7.6895Y6.951+0.738
5Y6.95110Y3.662+3.289
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.3313.475+4.856
TTM7.6894.059+3.630
YOY6.0425.472+0.570
5Y6.9516.027+0.924
10Y3.6626.357-2.695
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Galapagos N.V..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Galapagos N.V. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Galapagos N.V. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Galapagos N.V. assets are financed with 41.1% credit (debt) and the remaining percentage (100% - 41.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Galapagos N.V.:

  • The MRQ is 0.411. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.438. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.411TTM0.438-0.027
TTM0.438YOY0.476-0.038
TTM0.4385Y0.444-0.006
5Y0.44410Y0.349+0.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4110.334+0.077
TTM0.4380.332+0.106
YOY0.4760.262+0.214
5Y0.4440.373+0.071
10Y0.3490.386-0.037
1.4.2. Debt to Equity Ratio

Measures if Galapagos N.V. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Galapagos N.V. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 69.8% means that company has €0.70 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Galapagos N.V.:

  • The MRQ is 0.698. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.782. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.698TTM0.782-0.084
TTM0.782YOY0.911-0.129
TTM0.7825Y0.869-0.087
5Y0.86910Y0.614+0.255
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6980.375+0.323
TTM0.7820.395+0.387
YOY0.9110.315+0.596
5Y0.8690.433+0.436
10Y0.6140.469+0.145
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Galapagos N.V.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Galapagos N.V. generates.

  • Above 15 is considered overpriced but always compare Galapagos N.V. to the Biotechnology industry mean.
  • A PE ratio of 20.75 means the investor is paying €20.75 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Galapagos N.V.:

  • The EOD is 23.216. Based on the earnings, the company is fair priced.
  • The MRQ is 20.748. Based on the earnings, the company is fair priced.
  • The TTM is 40.808. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD23.216MRQ20.748+2.468
MRQ20.748TTM40.808-20.060
TTM40.808YOY-8.111+48.918
TTM40.8085Y12.385+28.423
5Y12.38510Y2.229+10.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD23.216-1.965+25.181
MRQ20.748-2.175+22.923
TTM40.808-2.595+43.403
YOY-8.111-4.412-3.699
5Y12.385-6.056+18.441
10Y2.229-6.408+8.637
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Galapagos N.V.:

  • The EOD is -4.914. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.392. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.664. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.914MRQ-4.392-0.522
MRQ-4.392TTM-4.664+0.272
TTM-4.664YOY-7.193+2.529
TTM-4.6645Y-11.501+6.837
5Y-11.50110Y-20.167+8.666
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.914-2.320-2.594
MRQ-4.392-2.652-1.740
TTM-4.664-3.416-1.248
YOY-7.193-6.076-1.117
5Y-11.501-8.343-3.158
10Y-20.167-8.978-11.189
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Galapagos N.V. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.82 means the investor is paying €0.82 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Galapagos N.V.:

  • The EOD is 0.915. Based on the equity, the company is cheap. +2
  • The MRQ is 0.818. Based on the equity, the company is cheap. +2
  • The TTM is 0.939. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.915MRQ0.818+0.097
MRQ0.818TTM0.939-0.122
TTM0.939YOY1.256-0.317
TTM0.9395Y2.546-1.606
5Y2.54610Y4.056-1.510
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9151.726-0.811
MRQ0.8181.836-1.018
TTM0.9392.045-1.106
YOY1.2563.063-1.807
5Y2.5463.614-1.068
10Y4.0564.055+0.001
2. Total Gains per Share
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Galapagos N.V. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.571-0.261+146%0.277+106%1.088-48%0.955-40%
Book Value Per Share--39.78339.061+2%40.317-1%37.062+7%23.684+68%
Current Ratio--8.9098.363+7%8.410+6%8.367+6%5.754+55%
Debt To Asset Ratio--0.4110.438-6%0.476-14%0.444-7%0.349+18%
Debt To Equity Ratio--0.6980.782-11%0.911-23%0.869-20%0.614+14%
Dividend Per Share----0%-0%-0%-0%
Eps--0.392-0.581+248%0.021+1756%-0.258+166%-0.163+142%
Free Cash Flow Per Share---1.852-2.041+10%-2.033+10%0.678-373%0.731-353%
Free Cash Flow To Equity Per Share---1.883-2.063+10%-2.037+8%2.444-177%3.248-158%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.744+34%
Intrinsic Value_10Y_max--0.316--------
Intrinsic Value_10Y_min---2.567--------
Intrinsic Value_1Y_max---6.635--------
Intrinsic Value_1Y_min---6.521--------
Intrinsic Value_3Y_max---14.855--------
Intrinsic Value_3Y_min---14.284--------
Intrinsic Value_5Y_max---16.949--------
Intrinsic Value_5Y_min---16.169--------
Market Cap2398654440.000+11%2143632663.0002414799229.500-11%3335711202.000-36%5603757589.800-62%4559885008.038-53%
Net Profit Margin--0.215-0.450+309%0.005+4148%-0.396+284%-0.235+209%
Operating Margin----0%-0.2170%-0.3580%-0.2640%
Operating Ratio--1.2991.433-9%1.247+4%1.740-25%1.730-25%
Pb Ratio0.915+11%0.8180.939-13%1.256-35%2.546-68%4.056-80%
Pe Ratio23.216+11%20.74840.808-49%-8.111+139%12.385+68%2.229+831%
Price Per Share36.400+11%32.53036.645-11%50.620-36%85.038-62%69.197-53%
Price To Free Cash Flow Ratio-4.914-12%-4.392-4.664+6%-7.193+64%-11.501+162%-20.167+359%
Price To Total Gains Ratio63.774+11%56.99357.0160%3163.100-98%596.363-90%359.825-84%
Quick Ratio--8.3317.689+8%6.042+38%6.951+20%3.662+128%
Return On Assets--0.006-0.008+237%0.000+2013%-0.006+205%-0.004+177%
Return On Equity--0.010-0.015+255%0.000+1892%-0.009+193%-0.006+163%
Total Gains Per Share--0.571-0.261+146%0.277+106%1.088-48%0.955-40%
Usd Book Value--2822633652.0002771462946.150+2%2860576560.000-1%2629608636.345+7%1680413254.508+68%
Usd Book Value Change Per Share--0.615-0.281+146%0.298+106%1.171-48%1.028-40%
Usd Book Value Per Share--42.83442.057+2%43.410-1%39.905+7%25.501+68%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.422-0.625+248%0.023+1756%-0.278+166%-0.175+142%
Usd Free Cash Flow---131378934.000-144840914.100+10%-144245499.000+10%48069648.345-373%42568383.592-409%
Usd Free Cash Flow Per Share---1.994-2.198+10%-2.189+10%0.729-373%0.787-353%
Usd Free Cash Flow To Equity Per Share---2.028-2.221+10%-2.193+8%2.631-177%3.497-158%
Usd Market Cap2582631235.548+11%2308049288.2522600014330.403-11%3591560251.193-36%6033565796.938-62%4909628188.155-53%
Usd Price Per Share39.192+11%35.02539.456-11%54.503-36%91.560-62%74.504-53%
Usd Profit--27811161.000-41202348.075+248%1498228.050+1756%-21949606.200+179%-13410270.892+148%
Usd Revenue--129233070.900146422586.400-12%155353543.725-17%158307793.185-18%100140402.235+29%
Usd Total Gains Per Share--0.615-0.281+146%0.298+106%1.171-48%1.028-40%
 EOD+5 -3MRQTTM+26 -6YOY+21 -115Y+16 -1610Y+16 -17

3.2. Fundamental Score

Let's check the fundamental score of Galapagos N.V. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1523.216
Price to Book Ratio (EOD)Between0-10.915
Net Profit Margin (MRQ)Greater than00.215
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.331
Current Ratio (MRQ)Greater than18.909
Debt to Asset Ratio (MRQ)Less than10.411
Debt to Equity Ratio (MRQ)Less than10.698
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.006
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Galapagos N.V. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.614
Ma 20Greater thanMa 5034.403
Ma 50Greater thanMa 10033.414
Ma 100Greater thanMa 20034.460
OpenGreater thanClose35.940
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets4,451,336
Total Liabilities1,829,776
Total Stockholder Equity2,621,560
 As reported
Total Liabilities 1,829,776
Total Stockholder Equity+ 2,621,560
Total Assets = 4,451,336

Assets

Total Assets4,451,336
Total Current Assets3,956,092
Long-term Assets3,956,092
Total Current Assets
Cash And Cash Equivalents 159,375
Short-term Investments 3,652,333
Net Receivables 46,918
Inventory 55,605
Other Current Assets 15,735
Total Current Assets  (as reported)3,956,092
Total Current Assets  (calculated)3,929,966
+/- 26,126
Long-term Assets
Goodwill 69,863
Intangible Assets 132,313
Long-term Assets Other 16,912
Long-term Assets  (as reported)495,244
Long-term Assets  (calculated)219,088
+/- 276,156

Liabilities & Shareholders' Equity

Total Current Liabilities444,036
Long-term Liabilities1,385,740
Total Stockholder Equity2,621,560
Total Current Liabilities
Accounts payable 121,129
Total Current Liabilities  (as reported)444,036
Total Current Liabilities  (calculated)121,129
+/- 322,907
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt14,147
Long-term Liabilities Other 31,448
Long-term Liabilities  (as reported)1,385,740
Long-term Liabilities  (calculated)45,595
+/- 1,340,145
Total Stockholder Equity
Total Stockholder Equity (as reported)2,621,560
Total Stockholder Equity (calculated)0
+/- 2,621,560
Other
Capital Stock293,937
Common Stock Shares Outstanding 65,897
Net Invested Capital 2,621,560
Net Working Capital 3,512,056



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-31
> Total Assets 
15,613
32,890
32,890
0
81,563
74,389
74,389
156,261
167,646
147,762
147,762
148,724
148,724
119,905
119,905
118,824
118,824
106,216
106,216
143,709
143,709
139,736
139,736
193,961
193,961
152,989
152,989
161,055
161,055
243,337
243,337
235,329
235,329
276,228
276,228
287,374
287,374
304,980
304,980
270,467
0
488,263
461,049
442,514
1,079,287
1,066,524
1,043,094
1,083,338
1,072,814
1,368,355
1,331,373
1,286,274
1,229,864
1,204,348
1,485,551
1,439,496
1,400,200
1,357,848
5,851,752
6,068,609
5,992,406
5,851,564
5,721,086
5,717,731
5,615,059
5,430,617
5,331,987
5,193,160
5,100,315
5,040,085
4,972,070
4,734,351
4,632,172
4,522,340
4,451,336
4,451,3364,522,3404,632,1724,734,3514,972,0705,040,0855,100,3155,193,1605,331,9875,430,6175,615,0595,717,7315,721,0865,851,5645,992,4066,068,6095,851,7521,357,8481,400,2001,439,4961,485,5511,204,3481,229,8641,286,2741,331,3731,368,3551,072,8141,083,3381,043,0941,066,5241,079,287442,514461,049488,2630270,467304,980304,980287,374287,374276,228276,228235,329235,329243,337243,337161,055161,055152,989152,989193,961193,961139,736139,736143,709143,709106,216106,216118,824118,824119,905119,905148,724148,724147,762147,762167,646156,26174,38974,38981,563032,89032,89015,613
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
174,622
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,007,232
992,122
1,284,957
1,243,839
1,197,647
1,135,735
1,107,881
1,390,400
1,328,851
1,259,244
1,208,604
5,651,013
5,865,927
5,780,264
5,622,005
5,463,769
5,369,347
5,310,922
5,129,494
5,015,997
4,861,854
4,750,700
4,533,192
4,462,397
4,236,850
4,155,294
4,032,147
3,956,092
3,956,0924,032,1474,155,2944,236,8504,462,3974,533,1924,750,7004,861,8545,015,9975,129,4945,310,9225,369,3475,463,7695,622,0055,780,2645,865,9275,651,0131,208,6041,259,2441,328,8511,390,4001,107,8811,135,7351,197,6471,243,8391,284,957992,1221,007,23200000000000000174,62200000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
124,417
0
0
0
0
0
0
0
0
0
0
0
0
0
0
973,241
953,385
1,262,061
1,218,856
1,151,211
1,108,186
1,066,766
1,343,668
1,290,796
1,222,901
198,994
4,270,724
1,861,616
2,743,573
2,384,220
2,087,797
2,135,187
2,553,950
2,642,639
2,834,378
2,233,368
1,254,279
972,796
675,519
508,117
124,135
98,024
159,375
159,37598,024124,135508,117675,519972,7961,254,2792,233,3682,834,3782,642,6392,553,9502,135,1872,087,7972,384,2202,743,5731,861,6164,270,724198,9941,222,9011,290,7961,343,6681,066,7661,108,1861,151,2111,218,8561,262,061953,385973,24100000000000000124,41700000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,919,216
2,978,805
3,182,276
3,220,805
3,026,278
2,560,743
2,363,969
2,039,787
2,469,809
3,389,098
3,456,184
3,686,557
3,585,945
3,865,915
3,776,913
3,652,333
3,652,3333,776,9133,865,9153,585,9453,686,5573,456,1843,389,0982,469,8092,039,7872,363,9692,560,7433,026,2783,220,8053,182,2762,978,8053,919,21600000000000000000000000000000000000000000000000000000000000
       Net Receivables 
2,169
2,120
2,120
0
9,786
5,729
5,729
24,846
24,847
24,702
24,702
26,500
23,581
19,761
19,761
26,427
26,427
20,131
20,131
32,489
32,489
26,173
26,173
63,546
63,546
14,304
14,304
28,857
28,857
16,083
16,083
33,242
33,242
26,540
26,540
31,979
31,979
20,061
20,061
13,794
0
11,801
19,163
16,057
15,075
17,625
18,127
23,479
26,164
15,642
17,740
41,789
20,086
33,762
37,006
33,533
26,992
42,067
32,642
80,110
49,180
45,190
139,299
173,399
180,347
113,600
126,802
128,601
78,521
64,057
54,374
28,194
41,443
41,450
46,918
46,91841,45041,44328,19454,37464,05778,521128,601126,802113,600180,347173,399139,29945,19049,18080,11032,64242,06726,99233,53337,00633,76220,08641,78917,74015,64226,16423,47918,12717,62515,07516,05719,16311,801013,79420,06120,06131,97931,97926,54026,54033,24233,24216,08316,08328,85728,85714,30414,30463,54663,54626,17326,17332,48932,48920,13120,13126,42726,42719,76119,76123,58126,50024,70224,70224,84724,8465,7295,7299,78602,1202,1202,169
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
2,919
0
0
2,532
2,532
1,604
1,604
2,990
2,990
3,139
3,139
3,843
3,843
2,193
2,193
3,647
3,647
4,522
4,522
4,634
4,634
4,520
4,520
2,944
2,944
3,005
3,005
1,394
0
5,751
4,653
10,918
5,642
6,981
6,848
3,642
8,215
6,936
6,939
4,368
7,170
7,086
9,446
4,104
9,351
6,970
8,838
4,438
8,706
10,319
15,868
33,909
15,882
9,286
15,030
9,305
10,404
13,147
20,437
2
27,897
40,766
15,735
15,73540,76627,897220,43713,14710,4049,30515,0309,28615,88233,90915,86810,3198,7064,4388,8386,9709,3514,1049,4467,0867,1704,3686,9396,9368,2153,6426,8486,9815,64210,9184,6535,75101,3943,0053,0052,9442,9444,5204,5204,6344,6344,5224,5223,6473,6472,1932,1933,8433,8433,1393,1392,9902,9901,6041,6042,5322,532002,919000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
140,956
149,244
200,739
202,682
212,142
229,559
257,318
348,384
304,136
301,123
315,990
331,306
349,615
506,893
509,673
497,501
476,877
490,193
495,244
495,244490,193476,877497,501509,673506,893349,615331,306315,990301,123304,136348,384257,318229,559212,142202,682200,739149,244140,95600000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
2,625
2,669
2,669
0
9,399
9,939
9,939
25,540
25,965
26,013
26,013
22,914
22,914
21,135
21,135
20,293
20,293
20,542
20,542
19,285
19,285
20,473
20,473
23,886
23,886
20,310
20,310
19,524
19,524
19,253
19,253
18,099
18,099
17,273
17,273
19,525
19,525
10,761
10,761
10,091
0
11,178
12,577
13,782
14,110
15,091
15,032
14,961
15,064
15,506
15,279
16,692
16,971
17,854
18,113
23,137
49,542
51,180
61,883
66,052
66,979
73,786
94,661
103,378
111,294
111,900
123,637
137,512
145,896
148,866
150,394
0
0
0
0
0000150,394148,866145,896137,512123,637111,900111,294103,37894,66173,78666,97966,05261,88351,18049,54223,13718,11317,85416,97116,69215,27915,50615,06414,96115,03215,09114,11013,78212,57711,178010,09110,76110,76119,52519,52517,27317,27318,09918,09919,25319,25319,52419,52420,31020,31023,88623,88620,47320,47319,28519,28520,54220,54220,29320,29321,13521,13522,91422,91426,01326,01325,96525,5409,9399,9399,39902,6692,6692,625
       Goodwill 
0
0
0
0
29,481
29,112
29,112
32,996
35,560
35,948
35,948
33,952
33,952
33,952
33,952
33,751
33,751
33,751
33,751
33,751
33,751
42,710
42,710
42,380
42,380
38,880
38,880
38,880
38,880
38,314
38,314
37,667
37,667
39,240
39,240
39,239
39,239
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
174,288
174,994
69,813
69,672
69,678
69,863
69,86369,67869,67269,813174,994174,2880000000000000000000000000000000039,23939,23939,24039,24037,66737,66738,31438,31438,88038,88038,88038,88042,38042,38042,71042,71033,75133,75133,75133,75133,75133,75133,95233,95233,95233,95235,94835,94835,56032,99629,11229,11229,4810000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,524
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,754
0
0
0
6,000
0
0
0
11,275
0
0
0
8,951
0
0
0
0
0
0
0
0
0
0
0
000000000008,95100011,2750006,0000001,75400000000000000000046,52400000000000000000000000000000000
       Intangible Assets 
447
422
422
0
34,350
33,690
33,690
42,445
53,404
53,164
53,164
40,042
40,042
40,019
40,019
37,910
37,910
37,960
37,960
37,231
37,231
58,248
58,248
55,914
55,914
50,068
50,068
49,494
49,494
48,135
48,135
47,091
47,091
47,768
47,768
47,071
47,071
1,862
1,862
2,015
0
1,575
1,517
1,550
1,382
1,226
1,150
1,023
963
859
747
2,495
2,555
1,403
2,058
3,632
6,497
7,191
23,492
24,927
33,856
39,254
41,114
67,566
65,738
63,072
59,623
60,103
0
32,346
38,493
146,353
140,914
136,470
132,313
132,313136,470140,914146,35338,49332,346060,10359,62363,07265,73867,56641,11439,25433,85624,92723,4927,1916,4973,6322,0581,4032,5552,4957478599631,0231,1501,2261,3821,5501,5171,57502,0151,8621,86247,07147,07147,76847,76847,09147,09148,13548,13549,49449,49450,06850,06855,91455,91458,24858,24837,23137,23137,96037,96037,91037,91040,01940,01940,04240,04253,16453,16453,40442,44533,69033,69034,3500422422447
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,377
5,713
5,993
28,164
13,945
9,522
8,647
37,504
4,465
4,422
4,455
2,472
7,881
8,388
7,832
5,778
5,702
17,927
16,912
16,91217,9275,7025,7787,8328,3887,8812,4724,4554,4224,46537,5048,6479,52213,94528,1645,9935,7136,37700000000000000000000000000000000000000000000000000000000
> Total Liabilities 
5,246
5,044
5,044
0
20,427
18,591
18,591
46,719
58,104
43,574
43,574
50,098
50,098
31,674
31,674
34,500
34,500
26,975
26,975
34,832
34,832
36,555
36,555
45,455
45,455
34,697
34,697
42,679
42,679
130,997
130,997
116,882
116,882
108,216
108,216
120,237
120,237
79,965
79,965
64,332
0
44,808
42,258
77,515
350,742
336,724
334,272
324,637
324,664
299,329
294,441
274,291
330,519
318,689
297,329
225,247
224,445
214,481
3,316,471
3,192,951
3,152,365
3,078,301
3,009,004
3,047,376
2,913,597
2,767,144
2,714,604
2,549,798
2,453,726
2,393,187
2,281,719
2,208,325
2,067,568
1,938,392
1,829,776
1,829,7761,938,3922,067,5682,208,3252,281,7192,393,1872,453,7262,549,7982,714,6042,767,1442,913,5973,047,3763,009,0043,078,3013,152,3653,192,9513,316,471214,481224,445225,247297,329318,689330,519274,291294,441299,329324,664324,637334,272336,724350,74277,51542,25844,808064,33279,96579,965120,237120,237108,216108,216116,882116,882130,997130,99742,67942,67934,69734,69745,45545,45536,55536,55534,83234,83226,97526,97534,50034,50031,67431,67450,09850,09843,57443,57458,10446,71918,59118,59120,42705,0445,0445,246
   > Total Current Liabilities 
3,608
3,688
3,688
0
14,065
12,305
12,305
29,655
29,278
22,704
22,704
43,361
43,361
25,532
25,532
29,751
29,751
22,787
22,787
31,344
31,344
28,053
28,053
38,223
38,223
27,818
27,818
35,360
35,360
124,367
124,367
109,014
109,014
99,294
99,294
112,559
112,559
75,977
75,977
60,357
0
40,299
37,251
72,412
104,736
111,549
129,826
103,791
127,984
130,678
154,531
171,699
223,631
246,586
269,102
219,905
199,450
188,712
631,300
571,793
622,626
618,538
601,744
635,274
605,362
576,985
575,494
566,474
562,896
550,725
532,207
522,538
522,904
475,073
444,036
444,036475,073522,904522,538532,207550,725562,896566,474575,494576,985605,362635,274601,744618,538622,626571,793631,300188,712199,450219,905269,102246,586223,631171,699154,531130,678127,984103,791129,826111,549104,73672,41237,25140,299060,35775,97775,977112,559112,55999,29499,294109,014109,014124,367124,36735,36035,36027,81827,81838,22338,22328,05328,05331,34431,34422,78722,78729,75129,75125,53225,53243,36143,36122,70422,70429,27829,65512,30512,30514,06503,6883,6883,608
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
316
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63
50
37
23
9
0
0
0
0
4,580
5,141
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000005,1414,58000009233750630000000000000031600000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
316
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63
50
37
23
9
0
0
0
0
4,580
5,141
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000005,1414,58000009233750630000000000000031600000000000000000000000000000000
       Accounts payable 
2,766
3,042
3,042
0
9,568
9,711
9,711
11,805
25,431
18,631
18,631
13,293
13,293
23,588
23,588
13,425
13,425
11,850
11,850
15,130
15,130
12,556
12,556
22,012
22,012
16,107
16,107
18,068
18,068
15,739
15,739
22,093
22,093
20,449
20,449
29,365
29,365
23,047
23,047
29,344
0
32,823
32,775
29,113
24,223
22,673
27,749
31,209
46,964
36,686
48,437
47,122
55,657
69,141
80,721
68,038
69,880
86,216
156,254
142,511
169,477
179,432
157,259
171,316
161,867
151,721
145,260
134,304
134,668
160,746
154,745
133,298
155,949
131,074
121,129
121,129131,074155,949133,298154,745160,746134,668134,304145,260151,721161,867171,316157,259179,432169,477142,511156,25486,21669,88068,03880,72169,14155,65747,12248,43736,68646,96431,20927,74922,67324,22329,11332,77532,823029,34423,04723,04729,36529,36520,44920,44922,09322,09315,73915,73918,06818,06816,10716,10722,01222,01212,55612,55615,13015,13011,85011,85013,42513,42523,58823,58813,29313,29318,63118,63125,43111,8059,7119,7119,56803,0423,0422,766
       Other Current Liabilities 
736
536
536
0
1,530
594
594
14,678
675
383
383
27,447
27,447
850
850
15,796
15,796
10,682
10,682
15,694
15,694
15,078
15,078
15,833
15,833
11,315
11,315
16,867
16,867
108,222
108,222
86,681
86,681
78,599
78,599
82,968
82,968
52,816
52,816
30,961
0
7,425
4,425
43,247
80,461
88,823
102,024
72,528
80,970
93,955
106,071
124,568
167,974
176,584
187,514
150,977
124,990
-1
-1
422,533
446,939
432,234
437,369
456,487
437,020
418,784
422,972
421,852
421,163
382,800
370,536
8,505
8,679
0
0
008,6798,505370,536382,800421,163421,852422,972418,784437,020456,487437,369432,234446,939422,533-1-1124,990150,977187,514176,584167,974124,568106,07193,95580,97072,528102,02488,82380,46143,2474,4257,425030,96152,81652,81682,96882,96878,59978,59986,68186,681108,222108,22216,86716,86711,31511,31515,83315,83315,07815,07815,69415,69410,68210,68215,79615,79685085027,44727,44738338367514,6785945941,5300536536736
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,995
25,769
2,685,171
2,621,158
2,529,739
2,459,763
2,407,260
2,412,102
2,308,235
2,190,159
2,139,110
1,983,324
1,890,830
1,842,462
1,749,512
1,685,787
1,544,664
1,463,319
1,385,740
1,385,7401,463,3191,544,6641,685,7871,749,5121,842,4621,890,8301,983,3242,139,1102,190,1592,308,2352,412,1022,407,2602,459,7632,529,7392,621,1582,685,17125,76924,99500000000000000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,457
19,661
19,558
18,856
20,384
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000020,38418,85619,55819,66120,457000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
214
63
63
11,875
23,637
18,110
18,110
4,698
4,698
4,252
4,252
3,392
3,392
2,531
2,531
1,960
1,960
2,704
2,704
3,672
3,672
3,813
3,813
4,465
4,465
4,381
4,381
5,079
5,079
6,074
6,074
5,319
5,319
3,848
3,848
3,860
0
4,420
4,931
5,040
245,956
225,138
204,423
220,837
196,680
168,651
139,910
102,592
106,888
72,103
28,227
5,342
4,586
5,312
2,665,510
2,601,600
2,510,883
2,439,379
2,385,310
2,389,066
2,286,059
2,168,730
2,119,982
1,963,669
1,872,541
1,825,587
1,733,753
0
0
0
0
00001,733,7531,825,5871,872,5411,963,6692,119,9822,168,7302,286,0592,389,0662,385,3102,439,3792,510,8832,601,6002,665,5105,3124,5865,34228,22772,103106,888102,592139,910168,651196,680220,837204,423225,138245,9565,0404,9314,42003,8603,8483,8485,3195,3196,0746,0745,0795,0794,3814,3814,4654,4653,8133,8133,6723,6722,7042,7041,9601,9602,5312,5313,3923,3924,2524,2524,6984,69818,11018,11023,63711,87563632140000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,460
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,872
0
0
0
13,334
0
0
0
11,796
0
0
0
0
0
0
0
000000011,79600013,33400014,872000000000000000000000000003,46000000000000000000000000000000000
> Total Stockholder Equity
10,367
27,846
27,846
27,846
61,136
55,798
55,798
109,542
109,542
104,188
104,188
98,626
98,626
88,231
88,231
84,324
84,324
79,241
79,241
108,877
108,877
103,181
103,181
148,506
148,506
118,292
118,292
118,376
118,376
112,340
112,340
118,447
118,447
168,012
168,012
167,137
167,137
225,015
225,015
206,135
206,135
443,455
418,791
364,999
728,545
729,800
708,822
758,701
748,150
1,069,026
1,036,932
1,011,983
899,345
885,659
1,188,222
1,214,249
1,175,755
1,143,367
2,535,281
2,875,658
2,840,041
2,773,263
2,712,082
2,670,355
2,701,462
2,663,473
2,617,383
2,643,362
2,646,589
2,646,898
2,690,351
2,526,026
2,564,604
2,583,948
2,621,560
2,621,5602,583,9482,564,6042,526,0262,690,3512,646,8982,646,5892,643,3622,617,3832,663,4732,701,4622,670,3552,712,0822,773,2632,840,0412,875,6582,535,2811,143,3671,175,7551,214,2491,188,222885,659899,3451,011,9831,036,9321,069,026748,150758,701708,822729,800728,545364,999418,791443,455206,135206,135225,015225,015167,137167,137168,012168,012118,447118,447112,340112,340118,376118,376118,292118,292148,506148,506103,181103,181108,877108,87779,24179,24184,32484,32488,23188,23198,62698,626104,188104,188109,542109,54255,79855,79861,13627,84627,84627,84610,367
   Retained Earnings -403,242-440,792-459,821-496,689-326,905-367,381-366,119-367,205-391,311-345,101-306,881-334,701-297,098-235,224-150,597-109,223-4,642-377,253-340,020-297,779-321,495-343,796-328,620-211,441-186,432-154,553-122,854-112,27200000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,283,650
2,268,585
2,703,583
2,708,114
2,723,671
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000002,723,6712,708,1142,703,5832,268,5851,283,650000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.